Adalimumab: Another Medication Related to Osteonecrosis of the Jaws?. (21st March 2016)

• Record Type: Journal Article
• Authors: Cassoni, Andrea; Romeo, Umberto; Terenzi, Valentina; Della Monaca, Marco; Rajabtork Zadeh, Oriana; Raponi, Ingrid; Fadda, Maria Teresa; Polimeni, Antonella; Valentini, Valentino
• Other Names: Gutierrez Luis M. J. Academic Editor.
• Is Part Of: Case reports in dentistry. Volume 2016(2016)
• Publication Date: 2016-03-21
• Subjects: Dentistry -- Case studies -- Periodicals; Oral medicine -- Case studies -- Periodicals; Oral Medicine; Dentistry; Dentistry; Oral medicine; Electronic journals; Periodical; Case studies; Periodicals; Case Reports; Fulltext; Internet Resources; Periodicals; 617.6
• DOI: 10.1155/2016/2856926
• Languages: English
• ISSNs: 2090-6447

Abstract

Abstract : Objective. The acronym MRONJ has been created in order to identify "Medication-Related Osteonecrosis of the Jaw, " observed after the use of Bisphosphonates, RANK ligand inhibitor, and antiangiogenic medications. Only a case of osteonecrosis of the jaw in a Chron's disease patient following a course of Bisphosphonate and Adalimumab therapy has been recently described, so that it has been supposed that also this medication could promote manifestation of osteonecrosis. Clinical Case . On August, 2014, a 63-year-old female with a history of idiopathic arthritis treated with medical treatment with Adalimumab from 2010 to 2013 presented referring pain in the right mandible. Results . This patient presented with nonexposed osteonecrosis of the jaw after placement, on September, 2010, of four titanium fixtures in the mandible. Conclusions . The authors suggest that the biologic therapy with an anti-TNF- α antibody might promote the manifestation of osteonecrosis and compromise oral healing capacity of the bone.